Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups
Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners...
Biotech
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program
China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine...
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...
Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine
China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing...
Luye Pharma’s Shandong Boan Bio Files for Hong Kong IPO
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has filed...
Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...
China’s Pharma Firms Collaborate on Generic Version of Sun Pharma’s Carbamazepine
Several China-based pharmaceutical companies, including Shanghai Zhongxi Sunve Pharmaceutical Co. Ltd, Shanghai Anbison Lab Co.,...
Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...
Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline
China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed...
Fosun Pharma’s Gland Pharma to Acquire French CDMO Cenexi for EUR 120 Million
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd...
Luye Pharma Initiates Phase II Study for LY 03014 in China
China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...
3D Medicines Set for IPO in Hong Kong, Aiming to Raise Up to USD 55 Million
China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO)...
Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...
Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC
Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...
Ascentage Pharma Receives Drug Production License for Suzhou Plant
Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...
Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu...
Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing
Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close...
PrimeLink Bio Raises Funds for ADC Development and R&D Expansion
Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a...
Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...